|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease显示文摘AIM: To compare the effi cacy and tolerability of S-pan- toprazole (20 mg once a day) versus racemic Panto- prazole (40 mg once a day) in the treatment of gastro- esophageal reflux disease (GERD). METHODS: This multi-centre, randomized, double-blind clinical trial consisted of 369 patients of either sex suf- fering from GERD. Patients were randomly assigned to receive either one tablet (20 mg) of S-pantoprazole once a day (test group) or 40 mg racemic pantoprazole once a day (reference group) for 28 d. Patients were evaluated for reduction in baseline on d 0, GERD symptom score on d 14 and 28, occurrence of any adverse effect during the course of therapy. Gastrointestinal (GI) endoscopy was performed in 54 patients enrolled at one of the study centers at baseline and on d 28. RESULTS: Signifi cant reduction in the scores (mean and median) for heart burn (P < 0.0001), acid regurgitation (P < 0.0001), bloating (P < 0.0001), nausea (P < 0.0001) and dysphagia (P < 0.001) was achieved in both groups on d 14 with further reduction on continuing the therapy till 28 d. There was a statistically signifi cant difference in the proportion of patients showing improvement in acid regurgitation and bloating on d 14 and 28 (P = 0.004 for acid regurgitation; P = 0.03 for bloating) and heart burn on d 28 (P = 0.01) between the two groups, with a higher proportion in the test group than in the refer- ence group. Absolute risk reductions for heartburn/acid regurgitation/bloating were approximately 15% on d 14 and 10% on d 28. The relative risk reductions were 26%-33% on d 14 and 15% on d 28. GI endoscopy showed no signifi cant difference in healing of esophagitis (P = 1) and gastric erosions (P = 0.27) between the two groups. None of the patients in either group reported any adverse effect during the course of therapy.CONCLUSION: In GERD, S-pantoprazole (20 mg) is more effective than racemic pantoprazole (40 mg) in improving symptoms of heartburn, acid regurgitation, bloating and equally effective in healing esophagitis and gastric erosions. The relative risk reduction is 15%-33%. Both drugs are safe and well tolerated. | Vikas G Pai Nitin V Pai Hemant P Thacker Jaisingh K Shinde Vijay P Mandora Subhash S Erram | 2006 | World Journal of Gastroenterology2006，12，37： | 19 |
| 2 | Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial显示文摘AIM: To investigate efficacy and safety of cetuximab combined with two chemotherapy regimens in patients with unresectable metastatic colorectal cancer (mCRC). METHODS: Randomized patients received cetuximab with 5-fluorouracil (5-FU), folinic acid (FA) and oxaliplatin (FOLFOX) 6 (arm A, n = 74) or 5-FU, FA and irinotecan (FOLFIRI) (arm B, n = 77). KRAS mutation status was determined retrospectively in a subset of tumors (n = 117). RESULTS: No significant difference was found between treatment arms A and B in the progression-free survival (PFS) rate at 9 mo, 45% vs 34%; median PFS, 8.6 mo vs 8.3 mo [hazard ratio (HR) = 1.06]; overall response rate (ORR) 43% vs 45% [odds ratio (OR) = 0.93] and median overall survival (OS), 17.4 mo vs 18.9 mo (HR = 0.98). Patients with KRAS wild-type tumors demonstrated improved PFS (HR = 0.55, P = 0.0051), OS, (HR = 0.62, P = 0.0296) and ORR (53% vs 36%) and in arm A, improved PFS (HR = 0.49, P = 0.0196), OS (HR = 0.48, P = 0.0201) and ORR (56%vs 30%), compared with patients with KRAS mutated tumors. In arm B no significant differences were found in efficacy by KRAS mutation status. Treatment in arms A and B was generally well tolerated. CONCLUSION: This study confirms that combinations of cetuximab with FOLFOX6 or FOLFIRI are effective and significantly improve clinical outcome in KRAS wild-type compared with KRAS mutated mCRC. | Janja Ocvirk Thomas Brodowicz Fritz Wrba Tudor E Ciuleanu Galina Kurteva Semir Beslija Ivan Koza Zsuzsanna Pápai Diethelm Messinger Ugur Yilmaz Zsolt Faluhelyi Suayib Yalcin Demetris Papamichael Miklós Wenczl Zrinka Mrsic-Krmpotic Einat Shacham-Shmueli Damir Vrbanec Regina Esser Werner Scheithauer Christoph C Zie-linski | 2010 | World Journal of Gastroenterology2010，16，25： | 17 |
| 3 | Risk for esophageal neoplasia in B arrett’s esophagus patients with mucosal changes indefinite for dysplasia显示文摘 | Bela Horvath Prabhdeep Singh Hao Xie Prashanthi N Thota Daniela S Allende Rish K Pai Deepa T Patil Thomas P Plesec John R Goldblum Xiuli Liu | 2015 | J Gastroenterol Hepatol2015，，： | 2 |
| 4 | Gastrointestinal stromal tumors:clinical profile,pathogenesis,treatment strategies and prognosis显示文摘 | Nowain A BhAkta H Pais S | 2005 | J Gastroenterol Hepatol2005，20，6： | 1 |
| 5 | Improving hierarchical cluster analysis: a new method with outlier detection and automatic clustering显示文摘 | ALMEIDA J A S BARBOSA L M S PAIS A A C C | 2007 | Chemometrics and Intelligent Labora- tory Systems2007，87，2： | 1 |
| 6 | Risk factors for early myocardial infarction in South Asians compared with individuals in other countries显示文摘 | Joshi P Islam S Pais P | 2007 | JAMA2007，297，3： | 1 |
| 7 | An exploration of the mother - child relationship between climacteric mothers and their adolescent danghters显示文摘 | Pai HC Lee S Tsao LI | 2004 | J Nuts Res2004，12，4： | 1 |
| 8 | Iberian Universities: a Characterisation from ESI Ranldngs显示文摘 | Cova T F G G Pais A A C C Formosinho S O J | 2013 | Scientomet- tics2013，94，3： | 1 |
| 9 | Radiofrequency assisted liver resection:Analysis of 604 consecutive cases显示文摘 | Pai M Frampton AE Mikhail S | 2012 | Eur J Surg Oncol2012，38，3： | 1 |
| 10 | Ecological quality assessment of small estuaries from the Portuguese coast based on fish assemblages indices显示文摘 | Inês Cardoso Miguel Pessanha Pais Sofia Henriques Luís Cancela da Fonseca Henrique N. Cabral | 2011 | Marine Pollution Bulletin2011，，5： | 1 |
| 11 | 显示文摘 | Loureiro Jose M Rodrigues Alirio E | 1998 | Journal of Chromatography A1998，827，： | 1 |
| 12 | Molecular characterization of tiny ring X chromosomes from females with functional X chromosome disomy and lack of cis X inactivation显示文摘 | JANI M M TORCHIA B S PAI G S | 1995 | Genomics1995，27，1： | 1 |
| 13 | Study of home-monitored night blood pressure and its correlation with left ventriculm' hypertrophy in treatment-naive hypertensive patients显示文摘 | PAI A U CHAKRAPANI S BHASKARAN U | 2012 | Singapore Med J2012，53，2： | 1 |
| 14 | PLD growth of CuAlO2 显示文摘 | Neumann-Spallart M Pai S P Pinto R | 2007 | Thin Solid Films2007，515，24： | 1 |
| 15 | Salmonella enterica serovar typhi strains isolated in Korea containing a multidrug resistance class 1 integron显示文摘 | Pai H Byeon JH Yu S | 2003 | Antimicrob Agents Chemother2003，47，6： | 1 |
| 16 | 显示文摘 | Loureiro Jose M Rodrigues Alirio E | 2000 | Separation Purification Technology2000，20，： | 1 |
| 17 | A complete equipment cir- cuit of a linear induction motor with sheet secondary 显示文摘 | PAI R M ION Boldea NASAR S A | 1988 | IEEE Transactions on Magnetics1988，24，1： | 1 |
| 18 | Microstructure and mechanical properties of Si and Sb added AZ91 magnesium alloy显示文摘 | SRINIVASAN A PILLAI U T S PAI B C | 2005 | Metallurgical and Materials Transactions A2005，36，8： | 1 |
| 19 | Effects acidity and molybdate concentration on the kinetics of the formation of the phosphoantimonylmolybdenum blue complex显示文摘 | PAI S C YANG C C RILEY J P | 1990 | Analytica Chimica1990，229，： | 1 |
| 20 | Inhibition of major histocompatibility complex I1 expression and antigen pro- cessing in murine alveolar macrophages by Mycobacterium boris BCG and the 19-kilodalton mycobacterial lipoprotein 显示文摘 | Fulton S A Reba S M Pai RK | 2004 | Infect Immun2004，72，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员